Seeking Alpha

Array BioPharma (ARRY +11%) gets a big boost from an upgrade to Overweight at Piper Jaffray this...

Array BioPharma (ARRY +11%) gets a big boost from an upgrade to Overweight at Piper Jaffray this morning, pushing the stock near a 5-month high. Piper says the company has a host of potentially positive study data due out later this year, and several partnering opportunities in FY13 that could bring in non-dilutive funding. This is encouraging, as the company already finished 2012 with $110M of cash, which the firm estimates would get ARRY through mid-2014.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs